Actio Biosciences

Jazz Pharmaceuticals (JAZZ) completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a potential first-in-class oral KCNT1 inhibitor for KCNT1-related epilepsy.

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15

As part of the deal, Actio Biosciences will spin out a new company focused on genetic rare neurological diseases.

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIE

PRN_FinancialWrapper

Actio launches dedicated patient resource to support families seeking information about the KYRON clinical trial at ActioTrials.com SAN DIEGO, May 8, 2026 - Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic ins

SAN DIEGO, January 6, 2026 - Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced that David Goldstein, Ph.D., co-founder and CEO, will present at the 44th

PRN_FinancialWrapper

Data to be presented during an oral platform presentation at the American Epilepsy Society Annual Meeting SAN DIEGO, December 5, 2025 - Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel prec

SAN DIEGO, November 24, 2025 - Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced it will present new preclinical data from its ABS-1230 program for the t